Company intelligence / Profile preview

Syncell

Taipei City*, Taipei, Taiwansyncell.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Syncell’s Microscoop® technology has been recognized as a top innovation by The Scientist and Fast Company. It enables hypothesis-free spatial proteomic discovery with high sensitivity/specificity. No clinical results reported since it’s a research tool/platform company rather than a therapeutic developer.

Therapeutic areas: Other
Modalities: Not directly therapeutic; platform for spatial proteomics and protein analysis (enables discovery across multiple modalities such as small molecules, mAbs, gene therapy targets)
Industry: Drug Discovery Services

Partnerships

No major pharma/biotech partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Syncell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syncell.

Explore the full profile